UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ALK alterations in salivary gland carcinomas

Virchows Archiv : an international journal of pathology, 2021-05, Vol.478 (5), p.933-941

2021

Volltextzugriff (PDF)

Folate/homocysteine metabolism and lung cancer risk among smokers

PloS one, 2019-04, Vol.14 (4), p.e0214462

2019

Volltextzugriff (PDF)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations

International journal of molecular sciences, 2023-08, Vol.24 (16), p.12840

2023

Volltextzugriff (PDF)

Serum lipid profile discriminates patients with early lung cancer from healthy controls

Lung cancer (Amsterdam, Netherlands), 2017-10, Vol.112, p.69-74

2017

Volltextzugriff (PDF)

Trimodality Treatment of Superior Sulcus Non-Small Cell Lung Cancer: An Institutional Series of 47 Consecutive Patients

Current oncology (Toronto), 2023-04, Vol.30 (5), p.4551-4562

2023

Volltextzugriff (PDF)

Cardiovascular complications after radiotherapy

Cardiology journal, 2020-12, Vol.27 (6), p.836-847

2020

Volltextzugriff (PDF)

Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours

Cancers, 2020-03, Vol.12 (3), p.683

2020

Volltextzugriff (PDF)

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838

2017

Volltextzugriff (PDF)

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Cancer treatment reviews, 2018-12, Vol.71, p.59-67

2018

Volltextzugriff (PDF)

Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis

Lung cancer (Amsterdam, Netherlands), 2021-08, Vol.158, p.97-106

2021

Volltextzugriff (PDF)

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study

Acta biochimica Polonica, 2017, Vol.64 (3), p.513-518

2017

Volltextzugriff (PDF)

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

Future oncology (London, England), 2021-12, Vol.17 (34), p.4657-4663

2021

Volltextzugriff (PDF)

Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer

The lancet respiratory medicine, 2024-09

2024

Volltextzugriff (PDF)

Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer

The journal of histochemistry and cytochemistry, 2021-11, Vol.69 (11), p.711-722

2021

Volltextzugriff (PDF)

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Clinical cancer research, 2018-07, Vol.24 (14), p.3334-3347

2018

Volltextzugriff (PDF)

Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer

The lancet respiratory medicine, 2020-06, Vol.8 (6), p.528-529

2020

Volltextzugriff (PDF)

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Cancer treatment reviews, 2014-07, Vol.40 (6), p.716-722

2014

Volltextzugriff (PDF)

Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment

Journal of contemporary brachytherapy, 2017-02, Vol.9 (1), p.7-13

2017

Volltextzugriff (PDF)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

Translational lung cancer research, 2021-04, Vol.10 (4), p.2032-2047

2021

Volltextzugriff (PDF)

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1233-1243

2019

Volltextzugriff (PDF)

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

Breast cancer research and treatment, 2009-09, Vol.117 (2), p.297-303

2009

Volltextzugriff (PDF)

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?

Journal of thoracic disease, 2022-08, Vol.14 (8), p.2738-2741

2022

Volltextzugriff (PDF)

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

Oncotarget, 2017-03, Vol.8 (10), p.17270-17278

2017

Volltextzugriff (PDF)

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

The lancet oncology, 2013-09, Vol.14 (10), p.916-917

2013

Volltextzugriff (PDF)

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1700-1709

2015

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(238)

Publikationsform

Sprache

Englisch
(263)
Polnisch
(12)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(157)
Life Sciences & Biomedicine
(156)
Oncology
(125)
Humans
(124)
Female
(69)
Middle Aged
(63)
Male
(61)
Respiratory System
(58)
Aged
(55)
Lung Neoplasms - Genetics
(51)
Adult
(47)
Lung Neoplasms - Pathology
(44)
Carcinoma, Non-Small-Cell Lung - Genetics
(42)
Lung Cancer
(42)
Lung Neoplasms - Drug Therapy
(42)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(37)
Prognosis
(34)
Carcinoma, Non-Small-Cell Lung - Pathology
(29)
Biological And Medical Sciences
(27)
Medical Sciences
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

ALK alterations in salivary gland carcinomas

Folate/homocysteine metabolism and lung cancer risk among smokers

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations

Serum lipid profile discriminates patients with early lung cancer from healthy controls

Trimodality Treatment of Superior Sulcus Non-Small Cell Lung Cancer: An Institutional Series of 47 Consecutive Patients

Cardiovascular complications after radiotherapy

Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer

Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Suchergebnisse filtern